Cerebrolysin
Get a source-linked, educational explanation from this profile.
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Cerebrolysin is listed as cognitive / neurotrophic peptide mixture.
- •Stroke recovery
- •Vascular & Alzheimer dementia (ex-US)
Regulatory status: Approved in ~50 countries; not FDA-approved.
Structure & Properties
Compound: Cerebrolysin; also known as FPF-1070.
Pharmacologic class: Cognitive / Neurotrophic Peptide Mixture.
Known delivery routes: Intravenous, Intramuscular.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
Porcine-brain-derived low-MW peptide mixture with BDNF/GDNF/NGF-like activity — promotes neurogenesis, synaptogenesis and neuroprotection.
- •Improved post-stroke motor recovery
- •Cognitive improvement in dementia
- •Neuroprotective
Human Research
Evidence grade: Clinical RCT (Limited)
Clinical RCT (Limited). Phase III CARS, CASTA trials.
Laboratory Research
Phase III CARS, CASTA trials
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
Daily IM or slow IV infusion, morning preferred. Typical courses: 10–20 days on, then break.
Potential interactions and combinations to avoid
- •Severe renal impairment
- •MAOIs — theoretical serotonergic interaction
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Allergic reaction (porcine origin)
- •Vertigo, agitation
- •Injection-site reactions
Contraindications
- •Severe renal impairment
- •Status epilepticus
- •Allergy to porcine peptides
- •Seizure disorder or history of epilepsy (lowered seizure threshold reported for some agents)
- •Bipolar disorder, psychosis, or active mania
- •Concurrent MAO inhibitors, stimulants, or serotonergic agents without psychiatric oversight
- •Recent intracranial haemorrhage or unstable neurologic injury
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Status epilepticus or severe renal impairment
- •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 10–50 mL/day IV (clinical); 5 mL/day IM (maintenance)
Frequency: Daily courses (10–21 days)
Cycling: 10–21 day courses, repeated quarterly.
Intramuscular
Outpatient courses.
5 mL ampoule, 21G needle. Deep IM (deltoid or gluteal), rotate side. Course: 10–20 consecutive days.
IV Infusion
Hospital / acute stroke protocols.
Diluted in 100–250 mL normal saline. Slow IV infusion 30–60 min. Clinician-only.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Semax, P21 in neuro-recovery protocols
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
What is Cerebrolysin?
In plain words
Cerebrolysin is an injectable mixture of small protein fragments and amino acids made from pig brain tissue. The body breaks down these components, and laboratory studies suggest the mixture may help nerve cells survive and form connections. Researchers study it for stroke recovery, Alzheimer’s disease and dementia linked to poor blood flow in the brain. Evidence of benefit is limited, and risks include allergic reactions, dizziness, agitation and reactions where it is injected.
Technical definition
Cerebrolysin (FPF-1070) is a porcine-brain-derived mixture of low-molecular-weight peptides and free amino acids, rather than a single defined peptide. Preclinical findings suggest neurotrophic activity resembling BDNF, GDNF and NGF, with effects on neuronal survival, neuron formation and synaptic connections; no single molecular target or receptor mechanism is established for the mixture. It is approved in approximately 50 countries, including for certain stroke and dementia indications, but is not FDA-approved; clinical randomized-trial evidence remains limited.
Function
Dosing
Recommended Time of Day
Morning — clinical protocols dose before noon.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Dorsogluteal (upper outer) — Upper outer quadrant of the buttock. Used for depot IM; alternate sides each cycle.
- Upper arm / deltoid — Back of the upper arm for SubQ; 2 in below the shoulder bone for IM.
- IV — clinician only — Antecubital vein or central line. Not for home administration.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
10–21 day courses, repeated quarterly.
Timing & Interactions
- ·Severe renal impairment
- ·MAOIs — theoretical serotonergic interaction
- ·Semax, P21 in neuro-recovery protocols
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Cerebrolysin and sync them to Vial Lab.
Benefits
- ·Improved post-stroke motor recovery
- ·Cognitive improvement in dementia
- ·Neuroprotective
Risks
- ·Allergic reaction (porcine origin)
- ·Vertigo, agitation
- ·Injection-site reactions
Contraindications
- ·Severe renal impairment
- ·Status epilepticus
- ·Allergy to porcine peptides
- ·Seizure disorder or history of epilepsy (lowered seizure threshold reported for some agents)
- ·Bipolar disorder, psychosis, or active mania
- ·Concurrent MAO inhibitors, stimulants, or serotonergic agents without psychiatric oversight
- ·Recent intracranial haemorrhage or unstable neurologic injury
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Status epilepticus or severe renal impairment
- ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
Approved in ~50 countries; not FDA-approved
Veterinary Use (Pets)
No established veterinary protocol for Cerebrolysin. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.